TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03972033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm.
Study: NCT04652648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Randomization was 2:1 to HCQ 200 mg BID or 41 observation for 10 days
Study: NCT01577121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin
Description: 50 mg / 6 hours during 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50 mg / 6 hours during 5 days
Study: NCT02033226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane
Description: AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Hydroxyapatite only)
Description: The placebo group was treated with Hydroxyapatite graft placement only.
Study: NCT06197282

Intervention type: PROCEDURE
Intervention: Major surgery involving general anesthesia
Description: EHR documented SAR-CoV-2 PCR nasopharyngeal swab results confirming Covid-19 status within one year of undergoing surgical procedure at Kern Medical Center.

Intervention type: PROCEDURE
Intervention: Major surgery involving general anesthesia
Description: EHR documented SAR-CoV-2 PCR nasopharyngeal swab results confirming Covid-19 status within one year of undergoing surgical procedure at Kern Medical Center.

Intervention type: PROCEDURE
Intervention: Major surgery involving general anesthesia
Description: EHR documented SAR-CoV-2 PCR nasopharyngeal swab results confirming Covid-19 status within one year of undergoing surgical procedure at Kern Medical Center.
Study: NCT03824509

Intervention type: OTHER
Intervention: Chart Review
Description: Study staff at PBMC (Cardiologist and two clinical researchers) will be responsible for maintaining all data related to this study in REDCap. Patient data to be included in this secondary data analysis will originate from MMC and PBMC.~Case-patient data to be included from MMC will be identified by an EPIC data request from Enterprise Reporting. The elements of the data request will be patients who have had a stroke or TIA, atrial fibrillation, and a transthoracic echocardiogram at MMC from 2014-2017.
Study: NCT02882477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Study: NCT02943083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Exercise
Description: Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Exercise
Description: Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.
Study: NCT00591578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
Study: NCT02882477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Study: NCT00374205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate plus Amodiaquine
Description: Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
Study: NCT02882477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Metformin
Study: NCT01097902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral one time only
Study: NCT03018717

Intervention type: OTHER
Group type: OTHER
Intervention: Telemonitoring Constant
Description: telemedicine of Constant

Intervention type: OTHER
Group type: OTHER
Intervention: Standard clinical care
Description: The patient will self-monitor heart rate, blood pressure, weight, diuresis, and capillary glycemia (in the case of diabetes)
Study: NCT01097902

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet oral one time only
Study: NCT00518349

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive bending function
Description: Colonoscope with a passive bending function
Study: NCT04180709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleepio
Description: Sleepio is an online cognitive behavioural therapy (CBT) based intervention designed to treat insomnia, conducted is 6 sessions. The program is an automated media-rich web-based application that is driven dynamically by baseline, adherence, performance and progress data. At the beginning of each session The Prof conducts a progressive review with the participant exploring the diary data submitted the week prior that includes sleep status and pattern, as well as progress based on goals previously set by the participant. The information, support and advice are personally tailored based on underlying algorithms.
Study: NCT00260650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart PACT Program
Description: patient activation intervention
Study: NCT04181398

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anthropometry
Description: * Actual Height and weight~* Calculated BMI from measured weight and height.~* Pubertal development (Tanner stage)~* Waist circumference~* Skin fold measurement (Triceps and Subscapular)~* Waist-to-height ratio will be calculated from measured height and waist circumference.
Study: NCT00518349

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No passive bending function
Description: Examination using standard colonoscope without passive bending function
Study: NCT01883037

Intervention type: OTHER
Intervention: Blood glucose results
Description: The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
Study: NCT04181398

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anthropometry
Description: * Actual Height and weight~* Calculated BMI from measured weight and height.~* Pubertal development (Tanner stage)~* Waist circumference~* Skin fold measurement (Triceps and Subscapular)~* Waist-to-height ratio will be calculated from measured height and waist circumference.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Blood pressure will be measured using an oscillometric, electronic device (Mindray). The blood pressure will be measured 3 times; the first measurement will not be taken into account and the mean of the second and third measurement will be considered as the real blood pressure.
Study: NCT02113293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyclASol®
Description: Cyclosporine A Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Vehicle Solution
Study: NCT04181398

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Blood pressure will be measured using an oscillometric, electronic device (Mindray). The blood pressure will be measured 3 times; the first measurement will not be taken into account and the mean of the second and third measurement will be considered as the real blood pressure.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral arterial tonometry
Description: The investigator will measure the pulse wave amplitude by using a finger plethysmograph (peripheral arterial tonometry). The investigator will use the EndoPAT device from Itamar Medical Ltd. At the end of the examination, the participants will be asked to give a VAS-score (Visual Analogue Pain scale).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral arterial tonometry
Description: The investigator will measure the pulse wave amplitude by using a finger plethysmograph (peripheral arterial tonometry). The investigator will use the EndoPAT device from Itamar Medical Ltd. At the end of the examination, the participants will be asked to give a VAS-score (Visual Analogue Pain scale).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: General questionnaire on cardiovascular risk factors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: General questionnaire on cardiovascular risk factors

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample for hs-CRP

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample for hs-CRP
Study: NCT01552434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT05251155

Intervention type: DIAGNOSTIC_TEST
Intervention: Distant best corrected visual acuity assessment
Description: Measuring distant visual acuity on snellen's chart using two methods and results were converted to equivalent logarithm of minimum angle of resolution to compare accuracy of mobile based chart to the standard vision chart.

Intervention type: DIAGNOSTIC_TEST
Intervention: Distant best corrected visual acuity assessment
Description: Measuring distant visual acuity on snellen's chart using two methods and results were converted to equivalent logarithm of minimum angle of resolution to compare accuracy of mobile based chart to the standard vision chart.
Study: NCT02081612

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: 12 educational weight management group session each addressing a different weight loss topic

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: 12 educational weight management group session each addressing a different weight loss topic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 12 weight loss acupuncture session using both body and auricular points.
Study: NCT00276848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine plus Cyclophosphamide
Description: fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, plus cyclophosphamide dosed at 250 mg/m2, administered intravenously daily over 30 minutes for 3 days, repeated every 28 days for a maximum of 6 courses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, , repeated every 28 days for a maximum of 6 courses
Study: NCT03110120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
Description: Serratus plane block realized with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
Description: local infiltration of the wound with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.5% levobupivacaine injectable solution with physiological saline
Description: Serratus plane block realized with 20 ml of injectable solution of physiological saline
Study: NCT04115722

Intervention type: OTHER
Intervention: IBD ACTIVIT
Description: Effect of IBD disease and activity of disease on coagulation parameters
Study: NCT03110120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% levobupivacaine injectable solution with physiological saline
Description: local infiltration of the wound with 20 ml of injectable solution of physiological saline
Study: NCT00911235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single 8 mg oral dose of fesoterodine

Intervention type: DRUG
Group type: OTHER
Intervention: fesoterodine plus fluconazole
Description: On Day 1, fluconazole (200 mg oral dose) will be given 1 hour before and approximately 11 hour following a single 8 mg oral dose of fesoterodine (fesoterodine SD). Fluconazole will also be administered 200 mg BID on the Day 2 (ie, at approximately 24 and 36 hours following the fesoterodine SD treatment given on Day 1)
Study: NCT00952913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 4 x 100-mg oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 4 x 100-mg oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 2 x 30-mg oral tablets, single daily doses for 2 days
Study: NCT02788240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg GCSF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20% Albumin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20% Albumin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowel wash
Study: NCT00696163

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
Study: NCT02036515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
Study: NCT02788240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bowel wash

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin 1- 4mg,if indicated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin 1- 4mg,if indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem or Imepenem, if indicated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem or Imepenem, if indicated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03611608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3316531
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3316531
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT01310283

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: xylitol mints and fluoride varnish
Description: Subjects in the intervention group will receive additional diet, oral hygiene handouts, more frequent professional fluoride application, and xylitol mints based on their caries risk levels.
Study: NCT04225156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod
Description: Intravenous infusion of efgartigimod
Study: NCT02342730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Specialist
Description: Referred to a weight loss specialist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete EORTC-QLQ questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Chart reviews are performed
Study: NCT01142921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-reflux Tannenbaum biliary stent
Description: Anti-reflux Tannenbaum biliary stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary Tannenbaum biliary stent
Description: Ordinary Tannenbaum biliary stent
Study: NCT01017315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baby talcum
Description: 50 grams apply locally prior cast application
Study: NCT02750423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DHCA+RCP
Description: During deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP) the participant is placed on cardiopulmonary bypass (heart-lung machine) and their body temperature is lowered to a range of 14-18 °C. Once the goal temperature has been achieved, the circulation is stopped and aortic arch replacement is performed in a bloodless surgical field. Blood will be pushed to the brain through arterial vessels, much like the natural blood flow pattern. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MHCA + SACP
Description: During moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA + SACP) the participant is placed on cardiopulmonary bypass (heart-lung machine0 and the native blood flow to the brain is temporarily suspended. The body is cooled to temperatures of ≤28°C and blood is administered to the brain via an artery in the neck during the period of arch reconstruction. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
Study: NCT01416662

Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine hydrochloride
Study: NCT03454620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: GC1118 combination with irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: GC1118 combination with FOLFIRI
Study: NCT01552434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT02729233

Intervention type: OTHER
Group type: OTHER
Intervention: patients receiving biopsies
Description: Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.